Non-Hodgkin Diffuse Lymphomas are known for their high responsiveness and effectiveness to chemotherapy compared to other indolent lymphomas. The combination of Doxorubicin, Vincristine, Cyclophosphamide, and Prednisone has been the standard treatment for many years. Today, with modern therapies, significant progress has been made in treating more than 50% of cases. Treatment with the anti-CD20 monoclonal antibody rituximab has dramatically improved the prognosis for patients with aggressive NHL.